Increasing Coverage and Efficiency of Measles, Mumps, and Rubella Vaccine and Introducing Universal Varicella Vaccination in Europe: A Role for the Combined Vaccine

@article{Vesikari2007IncreasingCA,
  title={Increasing Coverage and Efficiency of Measles, Mumps, and Rubella Vaccine and Introducing Universal Varicella Vaccination in Europe: A Role for the Combined Vaccine},
  author={Timo Vesikari and Catherine Sadzot-Delvaux and Bernard Rentier and Anne Gershon},
  journal={The Pediatric Infectious Disease Journal},
  year={2007},
  volume={26},
  pages={632-638}
}
Universal mass vaccination according to a 2-dose measles-mumps-rubella (MMR) vaccine schedule is recommended by the World Health Organization and is fundamental to the control of these important diseases. Very high coverage (first dose, ≥95%; second dose, ≥80%) is necessary to achieve and sustain high population immunity, and eventually interrupt indigenous transmission of these diseases. In 2006, the Advisory Committee on Immunization Practices issued a recommendation for 2 doses of varicella… 
Live Attenuated Measles Mumps and Rubella Vaccines: An Over View
TLDR
The use of MMR or the recently developed MMR-V (Varicella) vaccine combination benefited from the established clinical surveillance, efficient-technology transfer and proper manufacturing, in addition to the cost effectiveness of these vaccines.
Vaccines for measles, mumps, rubella, and varicella in children.
TLDR
The effectiveness, safety, and long- and short-term adverse effects associated with the trivalent MMR vaccine, containing measles, rubella, mumps, and varicella strains (MMR), or tetravalent vaccine, given to children aged up to 15 years are assessed.
Vaccines for measles, mumps, rubella, and varicella in children.
TLDR
The effectiveness, safety, and long- and short-term adverse effects associated with the trivalent MMR vaccine, containing measles, rubella, mumps, and varicella strains (MMR), or tetravalent vaccine, given to children aged up to 15 years are assessed.
Measles–Mumps–Rubella–Varicella Combination Vaccine (ProQuad®): A Guide to Its Use in Children in the EU
  • L. Scott
  • Medicine, Biology
    Pediatric Drugs
  • 2015
TLDR
Clinical data in young children indicates that vaccination with ProQuad® is as immunogenic as the component vaccines, provides long-term protection against these potentially serious childhood infections and has an acceptable safety profile.
Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore
TLDR
Both vaccines exhibited an acceptable safety profile in Taiwanese and Singaporean children and non-inferiority of MMRV new WS to MMRV in terms of post-dose-1 seroconversion rates was achieved for all vaccine antigens.
Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine: an open-labeled, randomized trial in healthy Korean children
TLDR
Based on the pre-specified non-inferiority criterion, SCRs of the MMRV vaccine were non- inferior to that elicited by MMR+V vaccines for all antigens except mumps.
New combination vaccines: integration into pediatric practice.
TLDR
Data suggest that the use of combination vaccines has positive effects on both rates and timeliness of immunizations, and there are also difficult-toquantify costs that may be greater with combined vaccines.
...
...

References

SHOWING 1-10 OF 122 REFERENCES
Immunogenicity and Safety of Two Doses of Tetravalent Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children
TLDR
Administration of 2 doses of the combined MMRV vaccine was as immunogenic and well-tolerated as separate injections of MMR and varicella vaccine, and did not induce an increased local or general reactogenicity compared with the separate administration.
Evaluation of a Quadrivalent Measles, Mumps, Rubella and Varicella Vaccine in Healthy Children
TLDR
A 1- or 2-dose regimen of MMRV is generally well-tolerated when administered to 12- to 23-month-old children and has a safety and immunogenicity profile similar to that of M-M-R®II and VARIVAX administered concomitantly.
Immunogenicity and Safety of a Second Dose of Measles–Mumps–Rubella–Varicella Vaccine in Healthy Children Aged 5 to 6 Years
TLDR
This experimental tetravalent MMRV vaccine appears well suited for use in national immunization programs in place of a second dose of MMR or MMR plus varicella in children who have already received a first dose of measles, mumps and rubella.
Safety and Immunogenicity of Early Vaccination with Two Doses of Tetravalent Measles-Mumps-Rubella-Varicella (MMRV) Vaccine in Healthy Children from 9 Months of Age
TLDR
Early vaccination with two doses of this experimental MMRV vaccine at 9 and 12 months of age was well-tolerated and at least as immunogenic as two dosesof separate licensed MMR and varicella vaccines.
Combination vaccines for childhood immunization.
TLDR
Over the last four decades, important new and improved vaccines to prevent childhood diseases have been developed; more are in the pipeline.
Mumps and rubella eliminated from Finland.
TLDR
Finland is the first country documented to be free of indigenous mumps and rubella (measles was eliminated in 1996), and major outbreaks probably can be avoided by maintaining high vaccination coverage and the 2-dose policy.
Evaluation of Live Attenuated Varicella Vaccine (Oka‐RIT Strain) and Combined Varicella and MMR Vaccination in 13–17‐Month‐Old Children
TLDR
This study confirmed that the Oka‐RIT strain varicella vaccine is safe and immunogenic in healthy young children, but failed to find a totally satisfactory combination for avaricella‐MMR vaccine.
Measles elimination in the Americas. Evolving strategies.
The strategy currently used to control measles in most countries has been to immunize each successive birth cohort through the routine health services delivery system. While measles vaccine coverage
Interruption of measles transmission in Gipuzkoa (Basque Country), Spain.
TLDR
Data indicate that the measles vaccination programme implemented has been effective, Nevertheless, to avoid measles outbreaks following viral introduction, high MMR vaccine coverage levels for the two doses have to be maintained.
Consensus: Varicella Vaccination of Healthy Children: A Challenge for Europe
TLDR
Routinevaricella vaccination for all healthy children between 12 and 18 months and to all susceptible children before their 13th birthday, in addition to catch-up vaccination in older children and adults who have no reliable history of varicella and who are at high risk of transmission and exposure are recommended.
...
...